Clearmind Medicine Inc. (CMND) shares tumbled 29.92% in after-hours trading on Wednesday, sliding to $0.0801. The clinical-stage biotech had already closed down 6.08% during regular trading at $0.11, so this was adding insult to injury.

The culprit? A reverse stock split so aggressive it makes your eyes water.

The Nasdaq Scramble

Clearmind announced Wednesday that it's implementing a 1-for-40 reverse stock split, effective December 15. Translation: every 40 shares you own will become one share. The company says this maneuver is designed to help it regain compliance with Nasdaq's minimum bid price requirement—that pesky rule that says your stock needs to trade above $1.00 to stay listed.

When your stock is trading at 11 cents, you've got a problem. The reverse split is essentially financial engineering to get back above that threshold, at least temporarily.

The Numbers Game

The reverse split will slash outstanding common shares from 59.99 million down to 1.50 million. That's a dramatic consolidation, though the Vancouver-based company notes its authorized share capital will remain unlimited.

One small mercy: no fractional shares will be issued. Any fractions get rounded up to the nearest whole share, so at least shareholders won't be dealing with partial ownership headaches.

How We Got Here

Clearmind's board approved the reverse split on November 12, following the company's articles of association. The biotech also stated it will make proportionate adjustments to the exercise price and number of shares for all outstanding options and warrants. Standard procedure, but important for anyone holding derivatives.

A Brutal Year

The bigger picture isn't pretty. Clearmind carries a market capitalization of just $6.86 million and has an annual trading range of $0.10 to $2.18. More painfully, the stock has crashed 91.41% over the past year.

That kind of decline explains why the company needs a reverse split in the first place. And investors clearly aren't thrilled about it—the after-hours selloff suggests serious skepticism about whether this financial maneuver will actually turn things around.